Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
British Journal of Cancer|June 7, 2024
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical featuresKevin D Arnold, Krystle L Ong, Gayathri Ravi, et al.
Cancer Causes & Control : CCC|November 25, 2015
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresMaryAnn E VanValkenburg, Gwendolyn I Pruitt, Ilene K Brill, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Leukemia|March 13, 2019
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyUjjawal H Gandhi, Robert F Cornell, Arjun Lakshman, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Pageof 2